sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 133 MCL (TRIANGLE)


News
1. Overview
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms


return to top

News


HO133 News

 

11JAN2017: Start Up meeting for participating HOVON sites was held in Utrecht.

 

18SEP2015: Participants Inquiry is sent to all HOVON sites. Planning is that study will first start in Germany (Q4 2015) after which HOVON will join with 25-30 sites in NL+BE.

 


1. Overview



Summary

Randomized, three-arm, parallel-group, open label, international phase III trial comparing six alternating courses of R-CHOP/R-DHAP (one cycle every 21 days) followed by ASCT versus the combination with ibrutinib in induction and maintenance (2 years) or the experimental arm without ASCT.


Status

planned


Type of study

Prospective randomized Phase III study


Echelon level

Level D


Echelon level specification

Agreements should be made with a higher echelon site for study parts that your center cannot execute.


Type of monitoring for this study

Study specific


Target number of patients

870


Date of first EC&CA submission

06-Apr-2017


2. Patient eligibility criteria



3. Registration (& randomization) of patients



Registration

Via EDC system of sponsor KU Munich.


4. Participating parties



Coordinating investigator(s)

Dr. J.K. Doorduijn (HOVON)


Trial manager

mw. N. Thuss (n.thuss@erasmusmc.nl)


Central data management

Will be done by sponsor KU Munich.


5. Participating sites



6. Instruction videos



7. Download documentation / forms




return to top